Trevi Therapeutics, Inc. TRVI Payments to Acquire Marketable Securities
Payments to Acquire Marketable Securities at other companies
Other financials
Where this comes from
Reported directly by Trevi Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireMarketableSecurities.
The official record: Trevi Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Trevi Therapeutics, Inc.'s payments to acquire marketable securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Trevi Therapeutics, Inc.'s payments to acquire marketable securities?
- Trevi Therapeutics, Inc. (TRVI) reported payments to acquire marketable securities of $8.49M in Q1 2026.
- How has Trevi Therapeutics, Inc.'s payments to acquire marketable securities changed year-over-year?
- Trevi Therapeutics, Inc.'s payments to acquire marketable securities decreased by 69.2% year-over-year, from $27.55M to $8.49M.
- What does payments to acquire marketable securities mean?
- Represents the cash outflows used to purchase investment-grade securities or other marketable financial instruments. This reflects the company's strategy for deploying excess cash into interest-bearing or liquid assets to preserve capital.